{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:14:48Z","timestamp":1787008488692,"version":"build-2736575974"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Sara Borrell Program Fellowship","award":["CD15\/00058"],"award-info":[{"award-number":["CD15\/00058"]}]},{"name":"Spanish Carlos III Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uterine leiomyomas (LM) and leiomyosarcomas (LMS) are considered biologically unrelated tumors due to their cytogenetic and molecular disparity. Yet, these tumors share morphological and molecular characteristics that cannot be differentiated through current clinical diagnostic tests, and thus cannot be definitively classified as benign or malignant until surgery. Newer approaches are needed for the identification of these tumors, as has been done for other tissues. The application of next generation sequencing enables the detection of new mutations that, when coupled to machine learning bioinformatic tools, advances our understanding of chromosomal instability. These approaches in the context of LM and LMS could allow the discovery of genetic variants and possible genomic markers. Additionally, the potential clinical utility of circulating cell-free tumor DNA could revolutionize the noninvasive detection and monitoring of these tumors. Here, we seek to provide a perspective on the molecular background of LM and LMS, recognizing their distinct molecular features that may lead to improved diagnosis and personalized treatments, which would have a measurable impact on women's reproductive health.<\/jats:p>","DOI":"10.1093\/biolre\/ioy195","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:02:00Z","timestamp":1535958120000},"page":"1115-1123","source":"Crossref","is-referenced-by-count":14,"title":["Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas"],"prefix":"10.1093","volume":"101","author":[{"given":"Aymara","family":"Mas","sequence":"first","affiliation":[{"name":"Reproductive Medicine Research Group, La Fe Health Research Institute, Valencia, Spain"},{"name":"Igenomix Foundation\/Instituto de Investigaci\u00f3n Sanitaria Hospital Cl\u00ednico (INCLIVA), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Sim\u00f3n","sequence":"additional","affiliation":[{"name":"Igenomix Foundation\/Instituto de Investigaci\u00f3n Sanitaria Hospital Cl\u00ednico (INCLIVA), Valencia, Spain"},{"name":"Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"issue":"4","key":"2020010204281856100_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2007.01.093","article-title":"Etiology, symptomatology, and diagnosis of uterine myomas","volume":"87","author":"Parker","year":"2007","journal-title":"Fertil Steril"},{"issue":"1","key":"2020010204281856100_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"14","key":"2020010204281856100_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine Fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"2020010204281856100_bib4","doi-asserted-by":"crossref","first-page":"h4887","DOI":"10.1136\/bmj.h4887","article-title":"Fibroids: diagnosis and management","volume":"351","author":"Lumsden","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"2020010204281856100_bib5","first-page":"517","article-title":"AAGL Advancing Minimally Invasive Gynecology Worldwide","volume":"21","author":"AAGL practice report: Morcellation during uterine tissue extraction","year":"2014","journal-title":"J Minim Invasive Gynecol"},{"issue":"5","key":"2020010204281856100_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/AOG.0b013e3181b9d222","article-title":"Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches","volume":"114","author":"Jacoby","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"12","key":"2020010204281856100_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical management of uterine sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020010204281856100_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/IGC.0000000000000911","article-title":"European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation","volume":"27","author":"Halaska","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2020010204281856100_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jmig.2015.12.012","article-title":"An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas","volume":"23","author":"Parker","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"2020010204281856100_bib10","first-page":"561","article-title":"Mesenchymal tumors of the uterus","volume-title":"Blaustein's Pathology of the Female Reproductive Tract","author":"Zaloudek","year":"2002"},{"issue":"15","key":"2020010204281856100_bib11","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(15)00375-7","article-title":"Morcellation of uterine leiomyomas: a plea for patient triage","volume":"16","author":"Amant","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020010204281856100_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"13","key":"2020010204281856100_bib13","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/1471-0528.14300","article-title":"Leiomyosarcoma and myomectomy: is the cat ever in the bag","volume":"123","author":"Munro","year":"2016","journal-title":"BJOG"},{"issue":"3","key":"2020010204281856100_bib14","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.ajog.2016.11.1039","article-title":"Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications","volume":"216","author":"Siedhoff","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2020010204281856100_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy?","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2020010204281856100_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/mco.2013.124","article-title":"The biology of uterine sarcomas: A review and update","volume":"1","author":"Kobayashi","year":"2013","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"2020010204281856100_bib17","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1245\/s10434-012-2834-0","article-title":"Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience","volume":"20","author":"Lusby","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2020010204281856100_bib18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/modpathol.2013.243","article-title":"MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma","volume":"27","author":"Bertsch","year":"2014","journal-title":"Mod Pathol"},{"issue":"8","key":"2020010204281856100_bib19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.humpath.2014.04.012","article-title":"Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics","volume":"45","author":"Jour","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"2020010204281856100_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/modpathol.2012.203","article-title":"MED12 mutations in leiomyosarcoma and extrauterine leiomyoma","volume":"26","author":"Ravegnini","year":"2013","journal-title":"Mod Pathol"},{"issue":"6","key":"2020010204281856100_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/14737159.2015.1019476","article-title":"Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq","volume":"15","author":"Bratman","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"issue":"224","key":"2020010204281856100_bib22","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"2020010204281856100_bib23","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S1470-2045(14)70326-2","article-title":"FDA likely to further restrict or ban morcellation","volume":"15","author":"Brower","year":"2014","journal-title":"Lancet Oncol"},{"key":"2020010204281856100_bib24","article-title":"FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids, April 17, 2014","author":"US Food and Drug Administration"},{"issue":"2","key":"2020010204281856100_bib25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2014.11.018","article-title":"Incidental power morcellation of malignancy: A retrospective cohort study","volume":"136","author":"Graebe","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2020010204281856100_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.2014.1093","article-title":"Evaluating the risks of electric uterine morcellation","volume":"311","author":"Kho","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"2020010204281856100_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmig.2014.08.781","article-title":"Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review","volume":"22","author":"Pritts","year":"2015","journal-title":"J Minim Invasive Gynecol"},{"issue":"6","key":"2020010204281856100_bib28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/AOG.0000000000002035","article-title":"Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation","volume":"129","author":"Stentz","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2020010204281856100_bib29","doi-asserted-by":"crossref","first-page":"594.e1","DOI":"10.1016\/j.ajog.2014.12.002","article-title":"Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation","volume":"212","author":"Tan-Kim","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2020010204281856100_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2014.206","article-title":"Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy","volume":"1","author":"Wright","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"2020010204281856100_bib31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00404-015-3696-z","article-title":"Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH)","volume":"292","author":"Bojahr","year":"2015","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"2020010204281856100_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10397-015-0878-4","article-title":"Options on fibroid morcellation: a literature review","volume":"12","author":"Br\u00f6lmann","year":"2015","journal-title":"Gynecol Surg"},{"issue":"1","key":"2020010204281856100_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2214\/AJR.11.7287","article-title":"Uterine sarcomas: then and now","volume":"199","author":"Shah","year":"2012","journal-title":"Am J Roentgenol"},{"issue":"6","key":"2020010204281856100_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2011.07.003","article-title":"Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential","volume":"25","author":"Ip","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"2020010204281856100_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PGP.0b013e31815ea7f5","article-title":"Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors","volume":"27","author":"Chen","year":"2008","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"2020010204281856100_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/gyno.1994.1194","article-title":"p53 alterations in uterine leiomyosarcomas versus leiomyomas","volume":"54","author":"de Vos","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2020010204281856100_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2559.2007.02699.x","article-title":"Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential","volume":"50","author":"O\u2019Neill","year":"2007","journal-title":"Histopathology"},{"issue":"4","key":"2020010204281856100_bib38","first-page":"370","article-title":"Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma","volume":"27","author":"Juang","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"issue":"4","key":"2020010204281856100_bib39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1525-1438.2002.01086.x","article-title":"Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus","volume":"12","author":"Goto","year":"2002","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"2020010204281856100_bib40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/bjc.2016.130","article-title":"MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas","volume":"114","author":"K\u00e4mpj\u00e4rvi","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"2020010204281856100_bib41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1518752113","article-title":"Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers","volume":"113","author":"Mehine","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2020010204281856100_bib42","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.fertnstert.2014.06.050","article-title":"Genomics of uterine leiomyomas: insights from high-throughput sequencing","volume":"102","author":"Mehine","year":"2014","journal-title":"Fertil Steril"},{"issue":"1","key":"2020010204281856100_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12943-017-0672-1","article-title":"Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors","volume":"16","author":"M\u00e4kinen","year":"2017","journal-title":"Mol Cancer"},{"issue":"2","key":"2020010204281856100_bib44","first-page":"289","article-title":"The HMGA proteins: a myriad of functions","volume":"32","author":"Cleynen","year":"2008","journal-title":"Int J Oncol"},{"issue":"2","key":"2020010204281856100_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cancergencyto.2010.08.005","article-title":"6p21 rearrangements in uterine leiomyomas targeting HMGA1","volume":"203","author":"Nezhad","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2020010204281856100_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1302736","article-title":"Characterization of uterine leiomyomas by whole-genome sequencing","volume":"369","author":"Mehine","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2020010204281856100_bib47","first-page":"1351","article-title":"Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15","volume":"63","author":"Quade","year":"2003","journal-title":"Cancer Res"},{"issue":"12","key":"2020010204281856100_bib48","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrc2271","article-title":"Roles of HMGA proteins in cancer","volume":"7","author":"Fusco","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2020010204281856100_bib49","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1093\/hmg\/dds051","article-title":"Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profiling of the t(12;14) and evidence in support of predisposing genetic heterogeneity","volume":"21","author":"Hodge","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2020010204281856100_bib50","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/ejhg.2013.33","article-title":"MED12 exon 2 mutations in histopathological uterine leiomyoma variants","volume":"21","author":"M\u00e4kinen","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"6053","key":"2020010204281856100_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"M\u00e4kinen","year":"2011","journal-title":"Science"},{"issue":"7","key":"2020010204281856100_bib52","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.27424","article-title":"MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups","volume":"131","author":"Markowski","year":"2012","journal-title":"Int J Cancer"},{"issue":"6","key":"2020010204281856100_bib53","doi-asserted-by":"crossref","first-page":"e40015","DOI":"10.1371\/journal.pone.0040015","article-title":"MED12 alterations in both human benign and malignant uterine soft tissue tumors","volume":"7","author":"P\u00e9rot","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2020010204281856100_bib54","doi-asserted-by":"crossref","first-page":"e33251","DOI":"10.1371\/journal.pone.0033251","article-title":"Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas","volume":"7","author":"McGuire","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"2020010204281856100_bib55","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.humpath.2013.01.006","article-title":"Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity","volume":"44","author":"de Graaff","year":"2013","journal-title":"Hum Pathol"},{"issue":"3","key":"2020010204281856100_bib56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/gcc.22029","article-title":"MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors","volume":"52","author":"Markowski","year":"2013","journal-title":"Genes Chromosom Cancer"},{"issue":"4","key":"2020010204281856100_bib57","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/PAT.0b013e328360bf97","article-title":"Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent\/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata)","volume":"45","author":"Rieker","year":"2013","journal-title":"Pathology"},{"issue":"4","key":"2020010204281856100_bib58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/his.12039","article-title":"Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours","volume":"62","author":"Matsubara","year":"2013","journal-title":"Histopathology"},{"issue":"1","key":"2020010204281856100_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.humpath.2013.08.005","article-title":"MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors","volume":"45","author":"Schwetye","year":"2014","journal-title":"Hum Pathol"},{"issue":"4","key":"2020010204281856100_bib60","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.fertnstert.2014.06.040","article-title":"MED12 mutation frequency in unselected sporadic uterine leiomyomas","volume":"10","author":"Heinonen","year":"2014","journal-title":"Fertil Steril"},{"issue":"4","key":"2020010204281856100_bib61","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"issue":"1","key":"2020010204281856100_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9440(10)63091-X","article-title":"Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors","volume":"164","author":"Lehtonen","year":"2004","journal-title":"Am J Pathol"},{"issue":"1","key":"2020010204281856100_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/hmg\/ddi431","article-title":"Distinct expression profile in fumarate-hydratase-deficient uterine fibroids","volume":"15","author":"Vanharanta","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2020010204281856100_bib64","first-page":"673","article-title":"Somatic deletion of the 5' ends of both the COL4A5 and COL4A6 genes in a sporadic leiomyoma of the esophagus","volume":"152","author":"Heidet","year":"1998","journal-title":"Am J Pathol"},{"issue":"5","key":"2020010204281856100_bib65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00467-010-1693-9","article-title":"Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2","volume":"26","author":"Uliana","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"2020010204281856100_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jmedgenet-2013-101670","article-title":"Deletion of the 5'exons of COL4A6 is not needed for the development of diffuse leiomyomatosis in patients with Alport syndrome","volume":"50","author":"S\u00e1","year":"2013","journal-title":"J Med Genet"},{"issue":"1","key":"2020010204281856100_bib67","first-page":"19","article-title":"Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas","volume":"59","author":"Schoenmakers","year":"1999","journal-title":"Cancer Res"},{"issue":"3","key":"2020010204281856100_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1098-2264(200007)28:3<235::AID-GCC1>3.0.CO;2-7","article-title":"Genetics of uterine leiomyomata","volume":"28","author":"Ligon","year":"2000","journal-title":"Genes Chromosom Cancer"},{"issue":"1","key":"2020010204281856100_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/gcc.22001","article-title":"Identification of CUX1 as the recurrent chromosomal band 7q22 target gene in human uterine leiomyoma","volume":"52","author":"Schoenmakers","year":"2013","journal-title":"Genes Chromosom Cancer"},{"issue":"6","key":"2020010204281856100_bib70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1043-2760(02)00603-3","article-title":"Prolactin as an autocrine\/paracrine growth factor in human cancer","volume":"13","author":"Ben-Jonathan","year":"2002","journal-title":"Trends in Endocrinology & Metabolism"},{"issue":"3","key":"2020010204281856100_bib71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/bbrc.2000.3835","article-title":"ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3","volume":"278","author":"Loechel","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2020010204281856100_bib72","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2009-2277","article-title":"Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability","volume":"95","author":"Yan","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020010204281856100_bib73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1541-7786.MCR-06-0331","article-title":"HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor- B","volume":"5","author":"Cleynen","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2020010204281856100_bib74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.onc.1207013","article-title":"Microarray screening for target genes of the proto-oncogene PLAG1","volume":"23","author":"Voz","year":"2004","journal-title":"Oncogene"},{"issue":"4","key":"2020010204281856100_bib75","first-page":"765","article-title":"PLAG1, the prototype of the PLAG gene family: versatility in tumour development","volume":"30","author":"Van Dyck","year":"2007","journal-title":"Int J Oncol"},{"issue":"6","key":"2020010204281856100_bib76","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3892\/ijo.2012.1641","article-title":"Cell type and context-specific function of PLAG1 for IGF2 P3 promoter activity","volume":"41","author":"Akhtar","year":"2012","journal-title":"Int J Oncol"},{"issue":"6","key":"2020010204281856100_bib77","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2007.01.031","article-title":"Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2 proliferation","volume":"46","author":"Cuevas","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"2020010204281856100_bib78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cancergencyto.2009.03.011","article-title":"Characterization of a recurrent t(1;2)(p36;p24) in human uterine leiomyoma","volume":"193","author":"van Rijk","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"43","key":"2020010204281856100_bib79","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1038\/sj.onc.1208784","article-title":"7q deletion mapping and expression profiling in uterine fibroids","volume":"24","author":"Vanharanta","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"2020010204281856100_bib80","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00432-012-1182-6","article-title":"Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization","volume":"138","author":"Raish","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2020010204281856100_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2004.11.009","article-title":"Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma","volume":"161","author":"Sandberg","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2020010204281856100_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.013","article-title":"Genetic aberrations in soft tissue leiomyosarcoma","volume":"275","author":"Yang","year":"2009","journal-title":"Cancer Lett"},{"issue":"2","key":"2020010204281856100_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/gcc.20018","article-title":"Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling","volume":"40","author":"Quade","year":"2004","journal-title":"Genes Chromosom Cancer"},{"issue":"2","key":"2020010204281856100_bib84","doi-asserted-by":"crossref","first-page":"e1005850","DOI":"10.1371\/journal.pgen.1005850","article-title":"Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12","volume":"12","author":"M\u00e4kinen","year":"2016","journal-title":"PLoS Genet"},{"issue":"6","key":"2020010204281856100_bib85","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int J Cancer"},{"issue":"6","key":"2020010204281856100_bib86","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/cas.13613","article-title":"Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma","volume":"109","author":"Tsuyoshi","year":"2018","journal-title":"Cancer Sci"},{"issue":"1","key":"2020010204281856100_bib87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/path.1711770111","article-title":"p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus","volume":"177","author":"Jeffers","year":"1995","journal-title":"J Pathol"},{"issue":"1","key":"2020010204281856100_bib88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"6041","key":"2020010204281856100_bib89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"issue":"7","key":"2020010204281856100_bib90","doi-asserted-by":"crossref","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","article-title":"Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway","volume":"8","author":"Lovejoy","year":"2012","journal-title":"PLoS Genet"},{"issue":"2","key":"2020010204281856100_bib91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAS.0000000000000324","article-title":"Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome","volume":"39","author":"Liau","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2020010204281856100_bib92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cjp2.11","article-title":"Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma","volume":"1","author":"Slatter","year":"2015","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"2020010204281856100_bib93","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.semcdb.2011.07.021","article-title":"Origins and activity of the Mediator complex","volume":"22","author":"Conaway","year":"2011","journal-title":"Semin Cell Dev Biol"},{"issue":"12","key":"2020010204281856100_bib94","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ejca.2015.04.023","article-title":"MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives","volume":"51","author":"Croce","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"2020010204281856100_bib95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ijc.21798","article-title":"Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients","volume":"119","author":"Ylisaukko-oja","year":"2006","journal-title":"Int J Cancer"},{"issue":"6","key":"2020010204281856100_bib96","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/jmg.2005.036400","article-title":"Increased risk of cancer in patients with fumarate hydratase germline mutation","volume":"43","author":"Lehtonen","year":"2006","journal-title":"J Med Genet"},{"issue":"3","key":"2020010204281856100_bib97","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2005.07.017","article-title":"Array comparative genomic hybridization analysis of uterine leiomyosarcoma","volume":"99","author":"Cho","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2020010204281856100_bib98","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/nnm.15.218","article-title":"Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers","volume":"11","author":"Miller","year":"2016","journal-title":"Nanomedicine"},{"issue":"10","key":"2020010204281856100_bib99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004320050319","article-title":"Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma","volume":"125","author":"Graeven","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2020010204281856100_bib100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2003.10.028","article-title":"Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma","volume":"92","author":"Mayerhofer","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2020010204281856100_bib101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acthis.2010.01.001","article-title":"Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma","volume":"113","author":"Sanci","year":"2011","journal-title":"Acta Histochem"},{"issue":"12","key":"2020010204281856100_bib102","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-11-3058","article-title":"A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma","volume":"18","author":"Shan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2020010204281856100_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/636849","article-title":"Primary leiomyosarcoma of bone: analysis of prognosis","volume":"2012","author":"Brewer","year":"2012","journal-title":"Sarcoma"},{"issue":"2","key":"2020010204281856100_bib104","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neo.2014.12.007","article-title":"Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome","volume":"17","author":"Barlin","year":"2015","journal-title":"Neoplasia"},{"issue":"2","key":"2020010204281856100_bib105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/gcc.1125","article-title":"Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis","volume":"31","author":"Hu","year":"2001","journal-title":"Genes Chromosom Cancer"},{"issue":"2","key":"2020010204281856100_bib106","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2012.11.021","article-title":"Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma","volume":"128","author":"Davidson","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2020010204281856100_bib107","first-page":"115","article-title":"Liquid Biopsy in the OMICS Era of Tumor Medicine","volume":"1","author":"Jiang","year":"2018","journal-title":"Open Access J Biomed Eng Appl"},{"issue":"21","key":"2020010204281856100_bib108","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2003.02.006","article-title":"Quantification of free circulating DNA as a diagnostic marker in lung cancer","volume":"21","author":"Sozzi","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020010204281856100_bib109","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4174\/astr.2014.86.3.136","article-title":"Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection","volume":"86","author":"Kim","year":"2014","journal-title":"Ann Surg Treat Res"},{"issue":"3","key":"2020010204281856100_bib110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1568009615666150211102503","article-title":"Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives","volume":"15","author":"Chiotaki","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"2020010204281856100_bib111","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.10526","article-title":"Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis","volume":"100","author":"Lecomte","year":"2002","journal-title":"Int J Cancer"},{"key":"2020010204281856100_bib112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fmed.2018.00009","article-title":"Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer","volume":"5","author":"Hench","year":"2018","journal-title":"Front Med"},{"key":"2020010204281856100_bib113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2018.03.027","article-title":"The identification and isolation of CTCs: A biological Rubik's cube","volume":"126","author":"Mansilla","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2020010204281856100_bib114","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrg3424","article-title":"A genomic view of mosaicism and human disease","volume":"14","author":"Biesecker","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"4","key":"2020010204281856100_bib115","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1078-0432.CCR-11-0564","article-title":"Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan","volume":"18","author":"Spindler","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020010204281856100_bib116","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1373\/clinchem.2013.206359","article-title":"Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients","volume":"59","author":"Taly","year":"2013","journal-title":"Clin Chem"},{"issue":"16","key":"2020010204281856100_bib117","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"2020010204281856100_bib118","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"2020010204281856100_bib119","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2020010204281856100_bib120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2020010204281856100_bib121","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"issue":"5","key":"2020010204281856100_bib122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-2143(03)00007-6","article-title":"Differential gene expression in uterine leiomyoma","volume":"141","author":"Skubitz","year":"2003","journal-title":"J Lab Clin Med"},{"issue":"5","key":"2020010204281856100_bib123","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/cncr.11586","article-title":"Differential gene expression in leiomyosarcoma","volume":"98","author":"Skubitz","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"2020010204281856100_bib124","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2005.09.055","article-title":"Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma","volume":"101","author":"Leiser","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2020010204281856100_bib125","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2353\/ajpath.2010.091150","article-title":"A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy","volume":"177","author":"Danielson","year":"2010","journal-title":"Am J Pathol"},{"issue":"1","key":"2020010204281856100_bib126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","article-title":"Lessons from the cancer genome","volume":"153","author":"Garraway","year":"2013","journal-title":"Cell"}],"container-title":["Biology of Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/biolreprod\/article-pdf\/101\/6\/1115\/31673668\/ioy195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/biolreprod\/article-pdf\/101\/6\/1115\/31673668\/ioy195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T04:29:32Z","timestamp":1577939372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biolreprod\/article\/101\/6\/1115\/5089963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":126,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,9,3]]},"published-print":{"date-parts":[[2019,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/biolre\/ioy195","relation":{},"ISSN":["0006-3363","1529-7268"],"issn-type":[{"value":"0006-3363","type":"print"},{"value":"1529-7268","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2018,9,3]]}}}